Nasal Spray Sends CRISPR to the Brain
By: Gorm Palmgren - Mar. 28, 2022 Most pharmaceuticals don't reach the brain, leaving cognitive impairments due to diseases like mucopolysaccharidoses (MPS) hard to treat. Now, a Brazilian research team has developed a method for nasal delivery of CRISPR reagents to the brain that improves MPS cognitive symptoms in mice. Experiments will proceed with monkeys later this year. |
Clinical Update: News on Two Cancer Gene Editing Trials
By: Karen O'Hanlon Cohrt - Mar. 24, 2022 This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial initiation in the U.S. In additional news, the first patient has been dosed in Wugen's WU-CART-007 trial for certain blood cancers. |
Using CRISPR-Cas9 to “Attack” Cancer Cells: A New Avenue for Personalised Cancer Treatment?
By: Christos Evangelou - Mar. 21, 2022 Researchers at Ulsan National Institute of Science and Technology in South Korea have developed a CRISPR-Cas9-based method to eliminate tumour cells. In this first proof-of-concept study, they confirm the feasibility of using CRISPR-Cas9 to selectively kill cancer cells in various disease models by targeting cancer-specific InDels. |
